Treatments include: atezolizumab with bevacizumab and chemotherapy in non-squamous NSCLC [15,16], atezolizumab with carboplatin and nab-paclitaxel chemotherapy [17], atezolizumab in monotherapy if PD-L1 TPS ≥ 50% or PD-L1-stained tumor-infiltrating immune cells cover ≥10 percent of the tumor area [6,18] and cemiplimab monotherapy if PD-L1 TPS ≥ 50% [19]. This evidence concerns the gene CD274 and neoplasm.